How pharma companies should respond to the rise of MAHA

By disregarding MAHA, life sciences companies are failing to stand up for themselves — and are turning a blind eye to the powerful cultural currents driving the movement. In this article published by MM+M in October 2025, Yogi Hendlin, Advisor, and Noël Theodosiou, Principal & CEO, suggest three fundamental changes the industry needs to make.

Full article here.